Migraine Drugs Market

Migraine Drugs Market (Treatment - Abortive (Triptans and Ergot Alkoids) and Prophylactic (Botulinum Toxin and Topiramate); Route of Administration - Oral and Injectable; Distribution Channel - Retail Pharmacies and Hospital Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

The prevailing unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers of the global migraine drugs market. Further, the growing population and increasing awareness among consumers regarding the availability of the migraine treatment drugs are prominent factors fueling the growth in the global migraine drugs market. Furthermore, development of advanced drugs by the migraine drugs manufacturers is some other factor influencing growth in the market. 

As per the Transparency Market Research, the global migraine drugs market reached a value of  US$2.72 bn in 2016 and is expected to reach a value of  US$3.72 bn by 2025. The global migraine drugs market is expected to register a steady CAGR 3.50% between 2017 and 2025.  The market is mainly segmented into three segments namely Treatment, Route of Administration, and Distribution Channel. 

Development of Advanced Migraine Drugs to Boost Growth of Migraine Drugs Market 

From the perspective of treatment, the global migraine drugs market is divided into- Abortive, and Prophylactic segments. Further, Abortive segment is classified into triptans, alkoids, ergot and others based on the drug class. While prophylactic treatment is segmented into botulinum toxin, topiramate and others. Among these treatment segments, abortive procedure is likely to dominant market share in the global migraine drugs market whereas prophylactic treatment segment is projected to register a healthy growth during the forecast period that is from 2017 to 2025. 

On the basis of route of administration segment, the global migraine drugs market is mainly segmented into oral, injectable and others. The other segment of route of administration includes nasal, spray, transdermal, patches and likewise. Among all of them, orally administrable drugs is likely to holds maximum potential for the global migraine market. And this is projected to continue in the upcoming years as well. This is mainly due to the low cost associated with the usage of oral drugs  and vast availability of the oral drugs as compared to the other form across the globe.  While on the basis of distribution channel the global migraine drugs market is segmented into hospital pharmacy and retail pharmacy. 

Global-Migraine-Drugs-Market.jpg

North America Holds Immense Potential in Migraine Drugs Market 

Based on Geography the global migraine drugs market segment is classified into five prime regions: North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Among all these five region, North America is expected to account highest share in the global migraine drugs market during the upcoming years. This is mainly because of the increasing healthcare investment by the private and government bodies. Apart from this, increasing cases of migraine and easy avaiblity of the specialized migraine treatment are the some other headwinds propelling growth in the market. The region is anticipated to register a healthy 3.40% CAGR between 2017 and 2025. 

The global migraine drug market depicts a fragmented competitive landscape owing to the presence of several players in the market. Some of the predominant players in the global migraine drugs market are Novartis AG, GlaxoSmithKline plc., Allergan Plc.,Avanir Pharmaceuticals, Inc., Janssen Pharmaceutical Company and ., Eisai Co.,

Migraine Drugs Market - Snapshot

The migraine drugs market features a fragmented and intensely competitive vendor landscape with the presence of several large players in the fray. To stay competitive, several large players are considering to launch revised version of their existing patent drugs and at the same launch new drugs. Besides this, large players in the migraine drugs market are striving for mergers and collaborations with regional players to consolidate their position in the global migraine drugs market.

North America is a prominent region in the global migraine drugs market. The presence of a well-established pharmaceutical industry in the region is a key factor for strong position of North America in the overall migraine drugs market. Moreover, high awareness for the risks of migraine, and the way it impacts quality of life accounts for substantial demand for migraine drugs in the region.

Meanwhile, the demand for migraine drugs is rising steadily in other key regions too. Firstly, the prevalence of migraine among individuals of all age groups that needs to be subsided with drugs fuels the migraine drugs market. Migraine is related to several factors, including food triggers, environment, hormones, or genetics. Nonetheless, so far, there has not been any line of treatment apart from prescription drugs to subside the pain. This creates massive opportunities in the migraine drugs market. In the coming years too, the migraine drugs market is anticipated to witness outstanding growth to be worth close to four billion dollars in the near future.

Key segments of the migraine drugs market based on treatment type are abortive and prophylactic. The abortive segment is further divided into alkoids, triptans, ergot, and others. On the other hand, prophylactic treatment segment is divided into topiramate, botulinum toxin, and others. The migraine drugs market is studied on the basis of route of administration as well. Oral, injectable, and others (transdermal, nasal spray, patches) are key segments of the migraine drugs market on the basis of route of administration.

The global migraine drugs market has been segmented as below:

by Treatment

  • Abortive
    • Triptans
    • Ergot Alkaloids
    • Others
  • Prophylactic
    • Botulinum Toxin
    • Topiramate
    • Others

by Route of Administration

  • Oral
  • Injectable
  • Others (Nasal Spray, Transdermal Patch, etc.)

by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others (Online Pharmacies, Drug Stores, etc.)

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Israel
    • Rest of Middle East and Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Migraine Drugs Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Product Definition
                4.1.2. Industry Evolution / Developments
         4.2. Market Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                         4.3.1.1. High prevalence of migraine and increasing transition from episodic to chronic migraine
                         4.3.1.2. Increasing investment in R&D and promising pipeline of novel drugs
                         4.3.1.3. Aging population and increasing proportion of female population
                         4.3.1.4. Increasing awareness among patients and high promotional investment by key players
                4.3.2. Restraints
                         4.3.2.1. Fragmented Market with vast availability of generic drugs
                         4.3.2.2. Ongoing investment in alternative therapies
                4.3.3. Opportunities
                4.3.4. Trends
         4.4. Migraine Drugs Market Analysis and Forecast, 2017 – 2025
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s five forces analysis
         4.6. Value Chain Analysis
         4.7. Global Prevalence of Migraine
         4.8. Pipeline Analysis
                4.8.1. Pipeline Analysis: Migraine Treatment Drugs
                4.8.2. Pipeline Analysis: Migraine Treatment Devices
         4.9. Market Outlook

    5. Global Migraine Drugs Market Analysis and Forecasts, By Treatment
         5.1. Introduction & Definition
         5.2. Key Findings
         5.3. Market Size (US$ Mn) Forecast, By Treatment
                5.3.1. Abortive
                         5.3.1.1. Triptans
                         5.3.1.2. Ergot Alkaloids
                         5.3.1.3. Others
                5.3.2. Prophylactic
                         5.3.2.1. Botulinum Toxin
                         5.3.2.2. Topiramate
                         5.3.2.3. Others
         5.4. New (Pipeline) Migraine Drugs Market Revenue (US$) Forecast, 2017-2025
         5.5. Market Attractiveness, By Treatment
         5.6. Key Trends

    6. Global Migraine Drugs Market Analysis and Forecasts, By Route of Administration
         6.1. Introduction & Definition
         6.2. Key Findings
         6.3. Market Size (US$ Mn) Forecast, By Route of Administration
                6.3.1. Oral
                6.3.2. Injectable
                6.3.3. Other
         6.4. Market Attractiveness, By Route of Administration
         6.5. Key Trends

    7. Global Migraine Drugs Market Analysis and Forecasts, By Distribution Channel
         7.1. Introduction & Definition
         7.2. Key Findings
         7.3. Market Size (US$ Mn) Forecast, By Distribution Chanel
                7.3.1. Retail Pharmacies
                7.3.2. Hospital Pharmacies
                7.3.3. Others
         7.4. Market Attractiveness, By Distribution Channel
         7.5. Key Trends

    8. Global Migraine Drugs Market Analysis and Forecasts, By Region
         8.1. Key Findings
         8.2. Global Market Scenario
         8.3. Market Size (US$ Mn) Forecast, By Region
                8.3.1. North America
                8.3.2. Europe
                8.3.3. Asia Pacific
                8.3.4. Latin America
                8.3.5. Middle East & Africa
         8.4. Market Attractiveness, By Region
         8.5. Key Trends, By Region

    9. North America Migraine Drugs Market Analysis and Forecast
         9.1. Key Findings
         9.2. Market Size (US$ Mn) Forecast, By Treatment
                9.2.1. Abortive
                         9.2.1.1. Triptans
                         9.2.1.2. Ergot Alkaloids
                         9.2.1.3. Others
                9.2.2. Prophylactic
                         9.2.2.1. Botulinum Toxin
                         9.2.2.2. Topiramate
                         9.2.2.3. Others
         9.3. Market Size (US$ Mn) Forecast, By Route of Administration
                9.3.1. Oral
                9.3.2. Injectable
                9.3.3. Others
         9.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                9.4.1. Retail Pharmacies
                9.4.2. Hospital Pharmacies
                9.4.3. Others
         9.5. Market Size by Value (US$ Mn) Forecast, By Country
                9.5.1. U.S.
                9.5.2. Canada
         9.6. Market Attractiveness Analysis
                9.6.1. By Treatment
                9.6.2. By Route of Administration
                9.6.3. By Distribution Channel
                9.6.4. By Country

    10. Europe Migraine Drugs Market Analysis and Forecast
         10.1. Key Findings
         10.2. Market Size (US$ Mn) Forecast, By Treatment
                10.2.1. Abortive
                         10.2.1.1. Triptans
                         10.2.1.2. Ergot Alkaloids
                         10.2.1.3. Others
                10.2.2. Prophylactic
                         10.2.2.1. Botulinum Toxin
                         10.2.2.2. Topiramate
                         10.2.2.3. Others
         10.3. Market Size (US$ Mn) Forecast, By Route of Administration
                10.3.1. Oral
                10.3.2. Injectable
                10.3.3. Others
         10.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                10.4.1. Retail Pharmacies
                10.4.2. Hospital Pharmacies
                10.4.3. Others
         10.5. Market Size by Value (US$ Mn) Forecast, By Country
                10.5.1. Germany
                10.5.2. France
                10.5.3. U.K.
                10.5.4. Spain
                10.5.5. Italy
                10.5.6. Rest of Europe
         10.6. Market Attractiveness Analysis
                10.6.1. By Treatment
                10.6.2. By Route of Administration
                10.6.3. By Distribution Channel
                10.6.4. By Country

    11. Asia Pacific Anti-migraine Drugs Market Analysis and Forecast
         11.1. Key Findings
         11.2. Market Size (US$ Mn) Forecast, By Treatment
                11.2.1. Abortive
                         11.2.1.1. Triptans
                         11.2.1.2. Ergot Alkaloids
                         11.2.1.3. Others
                11.2.2. Prophylactic
                         11.2.2.1. Botulinum Toxin
                         11.2.2.2. Topiramate
                         11.2.2.3. Others
         11.3. Market Size (US$ Mn) Forecast, By Route of Administration
                11.3.1. Oral
                11.3.2. Injectable
                11.3.3. Others
         11.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                11.4.1. Retail Pharmacies
                11.4.2. Hospital Pharmacies
                11.4.3. Others
         11.5. Market Size by Value (US$ Mn) Forecast, By Country
                11.5.1. India
                11.5.2. China
                11.5.3. Japan
                11.5.4. Australia & New Zealand
                11.5.5. Rest of Asia Pacific
         11.6. Market Attractiveness Analysis
                11.6.1. By Treatment
                11.6.2. By Route of Administration
                11.6.3. By Distribution Channel
                11.6.4. By Country

    12. Latin America Anti-migraine Drugs Market Analysis and Forecast
         12.1. Key Findings
         12.2. Market Size (US$ Mn) Forecast, By Treatment
                12.2.1. Abortive
                         12.2.1.1. Triptans
                         12.2.1.2. Ergot Alkaloids
                         12.2.1.3. Others
                12.2.2. Prophylactic
                         12.2.2.1. Botulinum Toxin
                         12.2.2.2. Topiramate
                         12.2.2.3. Others
         12.3. Market Size (US$ Mn) Forecast, By Route of Administration
                12.3.1. Oral
                12.3.2. Injectable
                12.3.3. Others
         12.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                12.4.1. Retail Pharmacies
                12.4.2. Hospital Pharmacies
                12.4.3. Others
         12.5. Market Size by Value (US$ Mn) Forecast, By Country
                12.5.1. Brazil
                12.5.2. Mexico
                12.5.3. Rest of Latin America
         12.6. Market Attractiveness Analysis
                12.6.1. By Treatment
                12.6.2. By Route of Administration
                12.6.3. By Distribution Channel
                12.6.4. By Country

    13. Middle East and Africa Anti-migraine Drugs Market Analysis and Forecast
         13.1. Key Findings
         13.2. Market Size (US$ Mn) Forecast, By Treatment
                13.2.1. Abortive
                         13.2.1.1. Triptans
                         13.2.1.2. Ergot Alkaloids
                         13.2.1.3. Others
                13.2.2. Prophylactic
                         13.2.2.1. Botulinum Toxin
                         13.2.2.2. Topiramate
                         13.2.2.3. Others
         13.3. Market Size (US$ Mn) Forecast, By Route of Administration
                13.3.1. Oral
                13.3.2. Injectable
                13.3.3. Others
         13.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
                13.4.1. Retail Pharmacies
                13.4.2. Hospital Pharmacies
                13.4.3. Others
         13.5. Market Size by Value (US$ Mn) Forecast, By Country
                13.5.1. Saudi Arabia
                13.5.2. South Africa
                13.5.3. Israel
                13.5.4. Rest of Middle East and Africa
         13.6. Market Attractiveness Analysis
                13.6.1. By Treatment
                13.6.2. By Route of Administration
                13.6.3. By Distribution Channel
                13.6.4. By Country

    14. Competition Landscape
         14.1. Market Player – Competition Matrix (By Tier and Size of companies)
         14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                14.2.1. AstraZeneca Plc.
                         14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.1.2. Product Portfolio
                         14.2.1.3. SWOT Analysis
                         14.2.1.4. Financial Overview
                         14.2.1.5. Strategic Overview
                14.2.2. Allergan Plc.
                         14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.2.2. Product Portfolio
                         14.2.2.3. SWOT Analysis
                         14.2.2.4. Financial Overview
                         14.2.2.5. Strategic Overview
                14.2.3. GlaxoSmithKline Plc.
                         14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.3.2. Product Portfolio
                         14.2.3.3. SWOT Analysis
                         14.2.3.4. Financial Overview
                         14.2.3.5. Strategic Overview
                14.2.4. Novartis AG
                         14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.4.2. Product Portfolio
                         14.2.4.3. SWOT Analysis
                         14.2.4.4. Financial Overview
                         14.2.4.5. Strategic Overview
                14.2.5. Pfizer, Inc.
                         14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.5.2. Product Portfolio
                         14.2.5.3. SWOT Analysis
                         14.2.5.4. Financial Overview
                         14.2.5.5. Strategic Overview
                14.2.6. Valeant Pharmaceuticals International, Inc.
                         14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.6.2. Product Portfolio
                         14.2.6.3. SWOT Analysis
                         14.2.6.4. Financial Overview
                         14.2.6.5. Strategic Overview
                14.2.7. Teva Pharmaceutical Industries, Ltd.
                         14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.7.2. Product Portfolio
                         14.2.7.3. SWOT Analysis
                         14.2.7.4. Financial Overview
                         14.2.7.5. Strategic Overview
                14.2.8. Eli Lilly & Company
                         14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.8.2. Product Portfolio
                         14.2.8.3. SWOT Analysis
                         14.2.8.4. Financial Overview
                         14.2.8.5. Strategic Overview
                14.2.9. Merck & Co., Inc.
                         14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.9.2. Product Portfolio
                         14.2.9.3. SWOT Analysis
                         14.2.9.4. Financial Overview
                         14.2.9.5. Strategic Overview
                14.2.10. Janssen Pharmaceutical Company (Johnson & Johnson)
                         14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.10.2. Product Portfolio
                         14.2.10.3. SWOT Analysis
                         14.2.10.4. Financial Overview
                         14.2.10.5. Strategic Overview
                14.2.11. Endo Pharmaceutical Inc.
                         14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.11.2. Product Portfolio
                         14.2.11.3. SWOT Analysis
                         14.2.11.4. Financial Overview
                         14.2.11.5. Strategic Overview
                14.2.12. Zosano Pharma Corporation
                         14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.12.2. Product Portfolio
                         14.2.12.3. SWOT Analysis
                         14.2.12.4. Financial Overview
                         14.2.12.5. Strategic Overview
                14.2.13. Alder BioPharmaceutical, Inc.
                         14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.13.2. Product Portfolio
                         14.2.13.3. SWOT Analysis
                         14.2.13.4. Financial Overview
                         14.2.13.5. Strategic Overview
                14.2.14. Avanir Pharmaceuticals, Inc.
                         14.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.14.2. Product Portfolio
                         14.2.14.3. SWOT Analysis
                         14.2.14.4. Financial Overview
                         14.2.14.5. Strategic Overview
                14.2.15. Eisai Co., Ltd.
                         14.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.2.15.2. Product Portfolio
                         14.2.15.3. SWOT Analysis
                         14.2.15.4. Financial Overview
                         14.2.15.5. Strategic Overview

    List of Tables

    Table 01: Pipeline Analysis, Migraine Therapy Drugs (1/3)
    Table 02: Pipeline Analysis, Migraine Therapy Drugs (2/3)
    Table 03: Pipeline Analysis, Migraine Therapy Drugs (3/3)
    Table 04: Pipeline Analysis, Migraine Therapy Devices
    Table 05: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 06: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 07: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 08: Global New Chronic Constipation Therapies Market Size (US$) Forecast, 2017-2025
    Table 09: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 10: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 11: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 12: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 13: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 14: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 15: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 16: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 17: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 18: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 19: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 20: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 21: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 22: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 23: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 24: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 25: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 26: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 27: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 28: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 29: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 30: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 31: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 32: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 33: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 34: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 35: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 36: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
    Table 37: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
    Table 38: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
    Table 39: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 40: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 41: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

    List of Figures

    Figure 01: Migraine Drugs Market, by Treatment, Market Size (US$ Mn), 2016 (A)
    Figure 02: Migraine Drugs Market Revenue (%), by Route of Administration, 2016 (A)
    Figure 03: Migraine Drugs Market Revenue (%), by Rigion, 2016 (A)
    Figure 04: Treatment Revenue (%), 2016
    Figure 05: Route of Administration Revenue (%), 2016
    Figure 06: Distribution Channel Revenue  (%), 2016
    Figure 07: Global Migraine Drugs Market Size (US$ Mn) Forecast, 2015–2025
    Figure 08 : Global Prevalence of Migraine
    Figure 09: Market Value Share, by Treatment (2016)
    Figure 10: Market Value Share, by Route of Administration (2016)
    Figure 11: Market Value Share, by Distribution Channel (2016)
    Figure 12: Global Migraine Drugs Market Value Share, by Treatment, 2016 and 2025
    Figure 13: Global Migraine Drugs Market Attractiveness, by Treatment, 2017–2025
    Figure 14: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Abortive Treatment, 2015–2025
    Figure 15: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prophylactic Treatment, 2015–2025
    Figure 16: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Triptans, 2015–2025
    Figure 17: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ergot Alkoids, 2015–2025
    Figure 18: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Abortive Treatment - Others, 2015–2025
    Figure 19: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Botulinum Toxin, 2015–2025
    Figure 20: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topiramate, 2015–2025
    Figure 21: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prophylactic Treatment - Others, 2015–2025
    Figure 22: Global Migraine Drugs Market Value Share, by Route of Administration, 2016 and 2025
    Figure 23: Global Migraine Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Figure 24: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
    Figure 25: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Injectable, 2015–2025
    Figure 26: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 27: Global Migraine Drugs Market Value Share, by Distribution Channel, 2016 and 2025
    Figure 28: Global Migraine Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 29: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
    Figure 30: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
    Figure 31: Global Migraine Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 32: Global Migraine Drugs Market Value Share, by Region, 2016 and 2025
    Figure 33: Global Migraine Drugs Market Attractiveness, by Region, 2017–2025
    Figure 34: North America Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 35: North America Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 36: North America Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
    Figure 37: North America Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 38: North America Migraine Drugs Market Value Share Analysis, by Country, 2016 and 2025
    Figure 39: North America Migraine Drugs Market Attractiveness Analysis, by Treatment
    Figure 40: North America Migraine Drugs Market Attractiveness Analysis, by Route of Administration
    Figure 41: North America Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
    Figure 42: North America Migraine Drugs Market Attractiveness Analysis, by Country
    Figure 43: Europe Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 44: Europe Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 45: Europe Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
    Figure 46: Europe Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 47: Europe Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 48: Europe Migraine Drugs Market Attractiveness Analysis, by Treatment
    Figure 49: Europe Migraine Drugs Market Attractiveness Analysis, by Route of Administration
    Figure 50: Europe Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
    Figure 51: Europe Migraine Drugs Market Attractiveness Analysis, by Country / Sub-region
    Figure 52: Asia Pacific Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 53: Asia Pacific Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 54: Asia Pacific Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
    Figure 55: Asia Pacific Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 56: Asia Pacific Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 57: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Treatment
    Figure 58: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Route of Administration
    Figure 59: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
    Figure 60: Asia Pacific Migraine Drugs Market Attractiveness Analysis, by Country
    Figure 61: Latin America Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 62: Latin America Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 63: Latin America Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
    Figure 64: Latin America Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 65: Latin America Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 66: Latin America Migraine Drugs Market Attractiveness Analysis, by Treatment
    Figure 67: Latin America Migraine Drugs Market Attractiveness Analysis, by Route of Administration
    Figure 68: Latin America Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
    Figure 69: Latin America Migraine Drugs Market Attractiveness Analysis, by Country / Sub-region
    Figure 70: Middle East & Africa Migraine Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 71: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 72: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2025
    Figure 73: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 74: Middle East & Africa Migraine Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
    Figure 75: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Treatment
    Figure 76: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Route of Administration
    Figure 77: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Distribution Channel
    Figure 78: Middle East & Africa Migraine Drugs Market Attractiveness Analysis, by Country

Copyright © Transparency Market Research, Inc. All Rights reserved